OM Pharma in Fribourg seeks a Medical Affairs Manager to lead key Bacterial Lysates products by building relationships with KOLs, specialists and GPs in respiratory and uro-gynecology, supplying scientific information, coordinating events, supervising study follow ups, and sharing insights with medical and commercial teams while ensuring regulatory compliance and pharmacovigilance. This field based role requires about 20 percent office presence in Villars-sur-Glâne, a Master’s, PhD or MD and at least three years in Medical Affairs or an MSL role, plus fluency in German, French and English and willingness to travel within Switzerland. To apply, tailor your CV to highlight cross functional collaboration, KOL engagement, and training experience, show Swiss regulatory awareness, and demonstrate concise, impactful communication.
Our Swiss Affiliate, based in Fribourg, is looking for a Medical Affairs Manager responsible for key products of our Portfolio the Bacterial Lysates. Joining a passionate team and reporting to the Medical Affairs Lead, your mission is to build and nurture strong relationships with KOLs, specialists and GPs.
Your main responsibilities are as follows:
Please note that this a field-based position requiring approximatively 20% presence at our office in Villars-sur-Glâne.
To carry out this mission, we are looking for a person with the following profile:
You describe yourself as a team player who enjoys working in a fast-paced, hands-on and flexible environment. Thanks to your scientific background and capacity for synthesis, you easily assimilate and interpret information and scientific data. You also demonstrate excellent communication skills, which allows you to interact efficiently with various stakeholders.
If you are looking for a position in a dynamic pharmaceutical company where you can make the difference and leave your footprint, apply as soon as possible and join OM Pharma!
OM Pharma is a global Geneva-based biopharmaceutical company. It is a leader in the prevention of recurrent respiratory and urinary tract infections and is also active in the treatment of vascular diseases.
It operates worldwide through a strong network of international partners and invests its profits in R&D to develop microbial derived immunotherapeutic products to treat acute and chronic immunological disorders resulting from inflammation and infections.
The company strives to improve the quality of life of patients around the world by providing access to better treatment of immunological imbalances.
For more information, visit the website: ompharma.com.